Anzeige
Mehr »
Samstag, 09.08.2025 - Börsentäglich über 12.000 News
Das Kupferangebot bricht ein - und dieser neue Fund kommt genau zur richtigen Zeit
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PKLC | ISIN: US04216R1023 | Ticker-Symbol: TG1N
Stuttgart
08.08.25 | 21:35
2,040 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ARMATA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ARMATA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,9602,14008.08.

Aktuelle News zur ARMATA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.06.Armata Pharmaceuticals, Inc. - 8-K, Current Report1
ARMATA PHARMACEUTICALS Aktie jetzt für 0€ handeln
21.05.ARMP Soars 72% in a Month Following Infectious Disease Study Success2
20.05.Armata stock price target raised to $9 at H.C. Wainwright6
19.05.Armata links bacteria-killing virus to clinical responses in phase 2 trial16
19.05.Armata reports positive results for phage therapy trial6
19.05.Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia172All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met AP-SA02 arm significantly improved clinical outcomes...
► Artikel lesen
14.05.Armata Pharmaceuticals, Inc. - 10-Q, Quarterly Report2
14.05.Armata Pharmaceuticals, Inc. - 8-K, Current Report2
14.05.Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update176LOS ANGELES, May 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company...
► Artikel lesen
01.05.Armata Pharmaceuticals erhält zusätzliche Finanzierung vom US-Verteidigungsministerium8
01.05.Armata Pharmaceuticals, Inc. - 8-K, Current Report7
02.04.Armata Pharmaceuticals, Inc. - 8-K, Current Report3
21.03.Armata Pharmaceuticals GAAP EPS of -$0.23, revenue of $1.2M9
20.03.Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update809 LOS ANGELES, March 20, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company...
► Artikel lesen
12.03.Armata Pharmaceuticals sichert sich Kredit in Höhe von 10 Millionen US-Dollar5
12.03.Armata Pharmaceuticals announces $10M secured credit agreement with Innoviva5
12.03.Armata Pharmaceuticals, Inc. - 8-K, Current Report1
19.12.24Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa ...155Results demonstrate that inhaled AP-PA02 provides a durable reduction of Pseudomonas aeruginosa in the lung, with a favorable safety and tolerability profile LOS...
► Artikel lesen
13.11.24Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update147LOS ANGELES, Nov. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on...
► Artikel lesen
12.11.24Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus ...136Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025 LOS ANGELES, Nov. 12, 2024 /PRNewswire/ --...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1